	US 12,264,349 B2
	Method for producing monoterpenoid compounds
Sarah O'Connor, Norwich (GB); and Benjamin Robert Lichman, Heslington (GB)
Assigned to John Innes Centre, Norwich (GB)
Appl. No. 17/058,825
Filed by John Innes Centre, Norwich (GB)
PCT Filed May 22, 2019, PCT No. PCT/GB2019/051409 § 371(c)(1), (2) Date Nov. 25, 2020, PCT Pub. No. WO2019/224536, PCT Pub. Date Nov. 28, 2019.
Claims priority of application No. 1808663 (GB), filed on May 25, 2018.
Prior Publication US 2021/0207183 A1, Jul. 8, 2021
Int. Cl. C12P 17/06 (2006.01); C12N 9/00 (2006.01); C12N 9/02 (2006.01); C12N 9/04 (2006.01); C12N 9/90 (2006.01); C12N 15/82 (2006.01)

CPC C12P 17/06 (2013.01) [C12N 9/0006 (2013.01); C12N 9/001 (2013.01); C12N 9/90 (2013.01); C12N 15/8243 (2013.01); C12Y 101/01 (2013.01); C12Y 103/01 (2013.01); C12Y 505/01 (2013.01)]

28 Claims

1. A method for producing a monoterpenoid compound, comprising:

(1) providing a genetically modified cell comprising one or more nucleic acids heterologous to the cell,

wherein the one or more nucleic acids encode one or more of:

an enzyme that comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 1 [NEPS1];

an enzyme that comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 2 [NEPS2]; and/or

an enzyme that comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 3 [NEPS3];

wherein the one or more of the enzymes are expressed in the genetically modified cell; and

(2) providing a monoterpenoid precursor to the genetically modified cell,

wherein the one or more of the enzymes act on the monoterpenoid precursor to produce the monoterpenoid compound.